Skip to main content
. 2024 Jan 18;103(6):1989–2001. doi: 10.1007/s00277-023-05603-w

Fig. 1.

Fig. 1

Response to daratumumab is not associated with CD38 expression, baseline EBV-DNA, or serum complement function. a CD38 expression by IHC. b Plasma EBV levels. c Serum complement CIC-C1q, C2, C3, and C4 levels. EBV, Epstein-Barr virus; IHC, immunohistochemical analysis; NR, nonresponder; R, responder; C, cycle; D, day; EOT, end of treatment; CIC, circulating immune complexes